Investment Thesis — Chemed Corporation
The market is mispricing Chemed by fixating on past regulatory and labor headwinds in its VITAS hospice segment, overlooking the undeniable demographic tailwinds for end-of-life care and the consistent, uncorrelated growth from its Roto-Rooter division. This creates an opportunity to acquire a diversified, defensive business at a discount to its long-term intrinsic value.
Catalysts
- Stronger-than-expected margin recovery and patient volume growth in the VITAS hospice segment.
- Favorable clarity or resolution on Medicare hospice reimbursement policies, reducing regulatory uncertainty.
- Continued robust growth and successful expansion initiatives within the Roto-Rooter plumbing and drain cleaning division.
Risk Factors
- Adverse changes in Medicare hospice reimbursement rates or regulatory scrutiny that negatively impact VITAS's profitability.
- Persistent labor shortages and wage inflation, particularly for nurses and caregivers, increasing operating costs for VITAS.
- Increased competition or economic downturns impacting demand for Roto-Rooter's services.
Key Debates
CHE 16.71x Fwd P/E expands to 20x by Q4 2024.
CHE reaches Analyst PT $475 by H2 2024, reversing sell-off.
Oversold CHE bounces 10% by Q3 2024, triggering short squeeze.